Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean aromatase inhibitor?
Displaying drugs 26 - 50 of 2437 in total

Indinavir

A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Approved
Matched Categories: … OCT1 inhibitors ... Enzyme Inhibitors ... UGT1A1 Inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors …

Roflumilast

Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium. The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4...
Approved
Matched Categories: … Phosphodiesterase Inhibitors ... Phosphodiesterase 4 Inhibitors …

Simvastatin

Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production...
Approved
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …

Candesartan cilexetil

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone...
Approved
Matched Description: … Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (strong) …

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor ... selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... Janus Kinase Inhibitors ... Protein Kinase Inhibitors …

Everolimus

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and...
Approved
Matched Description: … In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and …
Matched Categories: … mTOR Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …

Trametinib

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... MAP Kinase, antagonists & inhibitors …

Enfuvirtide

Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting...
Approved
Investigational
Matched Description: … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide …
Matched Categories: … HIV Fusion Inhibitors ... Fusion Protein Inhibitors ... Viral Fusion Protein Inhibitors …

Pantoprazole

Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... OAT3/SLC22A8 Inhibitors …

Trilaciclib

Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
Approved
Investigational
Matched Description: … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis …
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... MATE 2-K Inhibitors …

Lapatinib

Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …

Isocarboxazid

Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription...
Approved
Matched Categories: … Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Monoamine Oxidase Inhibitors, Non-Selective ... Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …

Vonoprazan

Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthermore, vonoprazan is 350-times more potent...
Approved
Investigational
Matched Description: … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. ... Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) …

Danicopan

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. ... alternative pathway, thereby working to address extravascular hemolysis when used in conjunction with C5 inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors …

Levothyroxine

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the...
Approved
Matched Categories: … OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (moderate) …

Captopril

Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Approved
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... ACE Inhibitors and Diuretics ... OAT1/SLC22A6 inhibitors ... P-glycoprotein inhibitors …

Moclobemide

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs)....
Approved
Investigational
Matched Description: … medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors …
Matched Categories: … Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Monoamine Oxidase A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …

Tranylcypromine

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …

Simoctocog alfa

Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the...
Approved

Metacycline

A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Approved
Investigational

Methyl nicotinate

Methyl nicotinate is the methyl ester of DB00627 that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation. For veterinary purposes, methyl nicotinate is used to...
Approved

Ranolazine

Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... P-glycoprotein inhibitors …

Suvorexant

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …

Etranacogene dezaparvovec

Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX. Clotting factors, including factor IX, are necessary components of the signaling cascade responsible for blood clotting and subsequent wound healing. Symptoms of hemophilia...
Approved
Investigational

Amiloride

A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with...
Approved
Matched Categories: … OCT2 Inhibitors …
Displaying drugs 26 - 50 of 2437 in total